Search

A recent study conducted at the State University of New York (SUNY) Buffalo introduced a novel approach to Alzheimer's Disease (AD) immunotherapy using a pentavalent peptide vaccine targeting multiple epitopes of amyloid-(3 and tau proteins. The research, supported by various organizations, demonstrated that the vaccine induced antibodies against both proteins, inhibited tau and amyloid pathologies in mice, and improved cognitive function without inducing inflammatory responses. The findings suggest that this nanoparticle-based vaccine warrants further investigation for treating early-stage AD. The study was published in Brain Behavior and Immunity and can be accessed for more information. [Extracted from the article]

A report from the Chinese Academy of Sciences discusses the development of a tobacco mosaic virus-based peptide vaccine for transdermal immunization using dissolving microneedles. The vaccine showed promising results in promoting dendritic cell maturation and inducing the production of specific antibodies. This research provides a potential strategy for creating effective peptide vaccines that are user-friendly and efficient. [Extracted from the article]

The FDA plays a critical role in ensuring the safety and effectiveness of flu vaccines, working closely with manufacturers and other agencies to develop vaccines that protect against the flu. Different types of flu vaccines are available, including those specifically approved for people aged 65 and older. The FDA's year-round efforts involve selecting flu virus strains, manufacturing vaccines, and ensuring quality control before distributing them for public use. Getting a flu vaccine annually is the best prevention against seasonal flu and its potential complications. [Extracted from the article]

Researchers at the Fourth Military Medical University in Shaanxi, China, have identified the protein DEPDC1 as playing a crucial role in the development and progression of various types of cancer. DEPDC1 is highly expressed in tumors and is involved in key signaling pathways essential for cell proliferation and survival. Clinical trials have shown promising results for DEPDC1-derived peptide vaccines, suggesting potential efficacy in cancer treatment. This comprehensive review aims to consolidate existing knowledge and pave the way for future research on the role of DEPDC1 in cancer biology. [Extracted from the article]

Researchers from Universidad Catolica de Murcia have conducted a critical review of emerging technologies in the development of monkeypox vaccines. Monkeypox is a zoonotic illness caused by the monkeypox virus, with particular health concerns for pregnant individuals, children, and those who are immunocompromised. The study highlights the need for ongoing research and innovation to enhance vaccine efficacy and safety, especially in the face of a recent global health emergency declared by the World Health Organization due to a monkeypox outbreak. The researchers aim to contribute to the development of robust and adaptable vaccine solutions for monkeypox and other related viral threats. [Extracted from the article]

A study conducted at the University of Pittsburgh focused on the development of a preventative cancer vaccine targeting MUC1, a glycoprotein overexpressed in cancer cells. The research involved the cloning of anti-MUC1 antibodies from vaccinated individuals and testing their efficacy in various effector functions related to tumor rejection. The study found that antibodies binding to specific epitopes on the MUC1 antigen were more efficient in mediating antibody-dependent cellular phagocytosis and trogocytosis, providing valuable insights for future therapeutic strategies. For more information, the full article can be accessed for free at the publisher's website. [Extracted from the article]

The article from Vaccine Weekly discusses research conducted at Lawrence Livermore National Laboratory on the potential of CT584 as a vaccine antigen against respiratory chlamydial challenge in mice. The study found that immunization with CT584 did not provide protection against the challenge, despite generating robust antibody responses. The researchers highlighted the speed and flexibility of cell-free protein synthesis (CFPS) for producing potential chlamydial antigens. For more information, readers can access the full article through the publisher, MDPI AG. [Extracted from the article]

The article discusses the development of proteolysis-targeting vaccines (PROTAVs) for enhancing tumor immunotherapy in combination with immune checkpoint blockade (ICB). PROTAVs are designed to improve T cell responses by facilitating antigen proteolytic processing and cross-presentation in antigen-presenting cells. In mouse models, PROTAVs, when combined with specific adjuvants, showed promising results in promoting CD8+ T cell responses and remodeling the tumor immune microenvironment, leading to regression of melanoma and HPV-associated tumors, as well as eradication of ICB-resistant large tumors. The study suggests that PROTAVs could be a versatile platform for effective tumor combination immunotherapy. [Extracted from the article]

A patent has been issued for a dendritic cell tumor vaccine developed by Shenzhen Frontiergate Biotechnology Co. Ltd. The vaccine utilizes chimeric antigen receptors (CARs) to activate dendritic cells in the immune suppressive tumor microenvironment. The CARs consist of an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain. The vaccine aims to stimulate tumor-specific T cells and enhance the body's immune response to treat tumors or prevent recurrence. The patent provides detailed information on the composition and components of the vaccine, including vectors, polynucleotides, and tumor antigens. [Extracted from the article]

A patent application from the Luxembourg Institute of Health (LIH) outlines a new approach to developing a COVID-19 vaccine. The proposed vaccine uses a protein complex made up of three polypeptides containing parts of the spike protein of the SARS-CoV-2 virus. This complex is designed to elicit a strong immune response by exposing neo-epitopes. The inventors believe that this protein-based vaccine could be administered multiple times and potentially address emerging variants of the virus. The vaccine has the potential to prevent SARS-CoV-2 infection. [Extracted from the article]

A patent has been issued to Think Therapeutics Inc. for a method of creating compact peptide vaccines using residue optimization. The goal of these vaccines is to train the immune system to recognize and respond to cancer cells or pathogens. The method involves selecting base peptides from a target protein, modifying them, and selecting a subset with a predicted vaccine performance. The invention also includes a system for selecting immunogenic peptide compositions and a computer-readable storage medium for determining these compositions. The patent provides potential advancements in cancer therapy and immunization. [Extracted from the article]

A recent study conducted by the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida explored the use of peptide vaccines in patients with ovarian cancer. The study focused on targeting the folate receptor alpha (FR alpha), which is overexpressed in the majority of high-grade epithelial ovarian cancers. The researchers conducted a randomized, double-blind, multicenter, phase II study to evaluate the safety and efficacy of a multi-epitope FR alpha peptide vaccine called TPIV200. The results showed that while the vaccine was well-tolerated, it did not significantly improve progression-free survival in patients. Further studies are needed to explore potential synergies using multiepitope vaccines targeting FR alpha. [Extracted from the article]

A recent article from Sorbonne Universite discusses advances in the treatment of IDH-mutant gliomas, a type of brain tumor. The researchers review therapeutic approaches that specifically target these gliomas and summarize ongoing clinical trials in this population. The article highlights the efficacy of the IDH inhibitor vorasidenib in grade 2 IDH-mutated gliomas and explores various strategies, including small-molecule inhibitors, immunotherapies, peptide vaccines, and agents targeting metabolic and epigenomic vulnerabilities. The research concludes that targeting mutant-IDH holds promise in treating progressive or recurrent IDH-mutant gliomas and may influence future treatment guidelines. [Extracted from the article]

A patent application has been filed for synthetic mini circular RNA constructs that can be used as vaccines. These constructs aim to address challenges with the stability and production of mRNA vaccines by offering improved biostability, smaller size, and the ability to activate innate immunity. The mini circular RNA vectors have the potential to produce a strong immune response and may be particularly useful in cancer treatment and infectious disease prevention. The patent application also includes methods for preparing and administering these circRNA vaccines. [Extracted from the article]

A study conducted by researchers from the University of Oxford in the United Kingdom has found that a peptide vaccine based on the HER2/neu antigen, in combination with the li-Key hybrid and the immunoadjuvant GM-CSF, shows promise as a treatment for triple-negative breast cancer. The study analyzed nine clinical trials involving HER2/neu-based vaccines and found that they elicited immunological responses and improved disease-free survival, particularly in the triple-negative breast cancer population. The researchers suggest that combining the li-Key hybrid vaccine with targeted drugs and adjuvants could further enhance the effectiveness of the vaccine. [Extracted from the article]

Chinese Academy of Sciences researchers have developed a novel cancer vaccine called ePAC, which utilizes a protein carrier called PEG10 to deliver genetically encoded neoantigens to dendritic cells (DCs). The vaccine has shown promising results in targeting and transporting neoantigens to DCs, promoting DC maturation, and inducing neoantigen-specific T cells. In mouse and humanized mouse tumor models, ePAC combined with anti-TIM-3 demonstrated significant antitumor efficacy. These findings suggest that ePAC could be a safe and effective cancer vaccine for clinical translation. [Extracted from the article]

Immatics Biotechnologies GmbH has been granted a patent for peptides that can be used in immunotherapy for prostate cancer and other types of cancer. Prostate cancer is a global health concern, and current treatment options vary depending on the stage of the cancer. Immunotherapy, which targets tumor-associated antigens, shows promise as a cancer treatment. The patent describes specific peptides and their variants that bind to major histocompatibility complex (MHC) molecules and stimulate T cells to react with the peptides. These peptides have the potential to be used in the development of cancer vaccines. This article provides an objective overview of research and discoveries in the fields of immunology and oncology, covering topics such as antigen-presenting cells, proteins, peptides, and vaccination. It also highlights the significance of these findings in clinical research and the treatment of diseases like prostate cancer. This resource is valuable for library patrons seeking to stay informed about the latest advancements in this field. [Extracted from the article]

The article focuses on recent research from Vanung University regarding advances in gene therapy and vaccine development. Topics discussed include novel vaccine platforms such as deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) vaccines, innovative administration routes like microneedles and inhalation, and the use of new biotechnologies including viral vectors and nanoparticles for vaccine delivery and cancer prevention.

UTime Limited has signed a non-disclosure agreement with Bowen Therapeutics Inc to acquire their laboratory at UMASS Medical School. This acquisition will support UTime's expansion in the global vaccine market and aid in the registration of a monkeypox vaccine through the FDA. Monkeypox has become a global concern, and Bowen Therapeutics has developed a hexavalent recombinant protein vaccine that shows promise in increasing virus-neutralizing antibodies and enhancing the protective effect of the vaccine. UTime will take over the laboratory, continue clinical trials, and assist in future vaccine development. This acquisition demonstrates UTime's commitment to addressing global public health challenges through innovation and technology. [Extracted from the article]

The article focuses on a clinical trial led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Maryland, assessing the safety and immune response of a personalized peptide vaccine (mBTCvax) combined with durvalumab and tremelimumab for advanced biliary tract cancer. It explains that the trial,, is set to start in September 2024 and aims to evaluate adverse events and immune responses over several years.

The article focuses on a U.S. patent application for a novel DNA vaccine strategy targeting human telomerase reverse transcriptase (hTERT) for cancer immunotherapy. It explains that the invention overcomes limitations of peptide-based vaccines by avoiding human leukocyte antigen (HLA) restriction and enhancing immune responses, and includes a nucleic acid construct encoding an hTERT protein without catalytic activity or nucleolar localization signal.

The article focuses on a U.S. patent application by Think Therapeutics Inc., related to peptide vaccines and immunogenic compositions. It explains that the patent involves nucleic acid sequences encoding specific amino acid sequences to enhance immune responses against cancerous cells or pathogens, with potential applications in cancer prevention and treatment. The patent covers immunogenic compositions that include these sequences, aiming to induce protective or therapeutic immune responses.

The article focuses on a study conducted at Medical University of Innsbruck in Australia, investigating factors influencing CD8+ T cell responses to cancer vaccines. The study found that a higher vaccine dose increases antigen-specific CD8+ T cell proportions, with intravenous administration yielding the highest proportion of these cells and the lowest anti-viral response. Additionally, the presence of a tumor and heterologous vaccine combinations further enhance CD8+ T cell responses.

The article focuses on a study conducted at University Hospital Tubingen in Germany evaluating a peptide-based vaccine for chronic lymphocytic leukemia (CLL) in patients undergoing Bruton's tyrosine kinase inhibitor therapy. The study found that the vaccine, developed from CLL-associated antigen peptides, aims to improve treatment responses and eliminate residual disease by inducing an anti-leukemic immune response.

A patent has been issued for a combination therapy involving peptide vaccines and pembrolizumab for the treatment of breast cancer. The patent, filed by Oncopep Inc., describes the use of immunogenic peptides that bind to MHC class 1 molecules to induce an immune response against cancer cells. The method involves administering pembrolizumab and specific peptides to patients with breast cancer, including triple negative breast cancer. The patent provides detailed information on the administration and dosage of the therapy. [Extracted from the article]

A recent study conducted by researchers at the University of Delhi focused on the development of a vaccine for Neisseria gonorrhoeae, the bacterium responsible for gonorrhea. The researchers used artificial intelligence and immuno-informatics to identify potential vaccine candidates. Through comprehensive analysis, they identified twenty proteins as potential targets for the vaccine. The study highlights the potential of these methods in the design of peptide-based vaccines for Neisseria gonorrhoeae. [Extracted from the article]

A patent application titled "Combined Agonist Adjuvant For Coronavirus Vaccine" has been published online. The inventors highlight the need for vaccines that can provide robust and long-lasting protection against SARS-CoV-2 and its variants. The patent application describes an immunogenic composition that includes a nanoemulsion, an agonist of retinoic acid-inducible gene I (RIG-I) and/or an agonist of a toll-like receptor (TLR), and a coronavirus vaccine. The composition aims to induce an immune response against the coronavirus and generate neutralizing antibodies and T cell responses. The patent application provides various methods of administering the immunogenic composition to induce an immune response in a subject. [Extracted from the article]

Researchers from the University of Jinan in China have made progress in the development of vaccines for Alzheimer's disease (AD). The researchers used immunoinformatic and molecular dynamics simulations to design and simulate an alternative vaccine called TAPAS, which was found to have similar properties to the experimental vaccine. They also predicted the 3D conformation of the ACI-24 peptide vaccine, which was effective against both full-length and truncated amyloid-beta oligomers. This study demonstrates the potential of using computational methods to design and simulate small peptide vaccines for AD. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the challenges faced by live-attenuated tetravalent dengue vaccines (LAVs) in stimulating a balanced immune response to all four dengue virus serotypes. The uneven replication of vaccine serotypes can lead to a dominant response to one serotype, increasing the risk of severe dengue. The study explores the potential of protein subunit vaccines as an alternative, focusing on the dengue virus 2 envelope protein. The researchers found that stable homodimers of the envelope protein stimulated a more complex and diverse immune response compared to the wild-type monomer, suggesting the promise of dengue virus 2 envelope homodimers as subunit vaccines. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A preprint abstract discusses the potential of tumor neoantigen peptide vaccines for cancer immunotherapy. The abstract highlights the challenges of efficiently delivering peptides and adjuvants to antigen-presenting cells in vivo. The researchers propose a novel protein carrier called ePAC, which is designed to self-assemble into endogenous virus-like particles (eVLP) and deliver genetically encoded neoantigens to dendritic cells. The study shows promising results in mouse and humanized mouse tumor models, suggesting that ePAC could be used as a safe and effective cancer vaccine for antitumor therapy. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted at Virginia Commonwealth University has developed a personalized peptide vaccine targeting neoantigens for pancreatic ductal adenocarcinoma (PDAC). The researchers used RNA sequencing to identify prevalent gene mutations in patient tumor tissue and developed a personalized vaccine that targeted 100 highly prevalent gene mutations. The vaccine was composed of neoantigens, allowing for a more precise and targeted immune response against cancer cells. This study is the first to design a personalized peptide cancer vaccine using human patient data to identify gene mutations associated with a specific tumor. [Extracted from the article]

A recent study conducted at Weill Cornell Medicine Cornell University examined the association between prenatal respiratory syncytial virus (RSV) vaccination and perinatal outcomes. The study found that the nonadjuvanted bivalent RSV vaccine was not associated with an increased risk of preterm birth (PTB) or other adverse perinatal outcomes. However, there was a slightly increased risk of hypertensive disorders of pregnancy (HDP) in the time-dependent model. These findings support the safety of prenatal RSV vaccination, but further research is needed to investigate the risk of HDP. [Extracted from the article]

A recent study conducted by researchers from Umea University in Sweden has shown that a vaccine targeting the histone mutation H3K27M can induce an immune response in patients with diffuse midline glioma. The study focused on one patient who has been in remission for over 3 years and found that the vaccine, named H3-vac, induced a CD4(+) T-cell-specific immune response and expanded the repertoire of polyclonal H3K27M-specific T-cell receptors. The researchers believe that this study paves the way for personalized therapies using immunogenic T- and B-cell responses against different tumor types. [Extracted from the article]

According to a preprint abstract, researchers are investigating the potential for a vaccine against rhinovirus (RV), which is associated with significant morbidity and hospitalization in people with chronic lung disease. Currently, there is no approved RV vaccine or antiviral. The high diversity of RV serotypes makes it impractical to create a broadly protective vaccine using traditional methods. However, the researchers suggest that directing the immune response towards conserved but less dominant epitopes, such as the capsid protein VP4, could be a more feasible strategy. They found that correctly displayed VP4 peptides can recapitulate virus-like antigenicity, which could inform the design of future RV vaccines. [Extracted from the article]

A patent application titled "Compositions Comprising Self-Assembling Vaccines And Methods Of Using The Same" has been published online. The application discusses the challenges in producing nanoparticle vaccines and proposes an alternative approach using computational protein engineering and synthetic DNA delivery. The application describes the development of DNA-launched nano-vaccines that can self-assemble in vivo and induce stronger immune responses compared to monomeric vaccines. The technology shows promise in the rapid development of vaccines and immunotherapies for multiple diseases. The application also includes specific details about the nucleic acid sequences and viral antigens used in the compositions. This patent application describes a pharmaceutical composition that includes a nucleic acid sequence encoding a self-assembling polypeptide and a viral antigen. The composition can be administered to a subject to vaccinate against a virus, induce an immune response, neutralize viruses, or stimulate an immune response against a specific virus. The composition can be administered through various methods such as oral, parenteral, or topical administration. The patent application also describes a nanoparticle composition that includes a self-assembling polypeptide, a viral antigen, and a CD40L polypeptide. These compositions have potential applications in treating viral infections, including HIV-1. [Extracted from the article]

A recent study conducted at the University of Virginia has found that multi-peptide vaccines can remain stable and retain their amino acid sequence identity for up to five years when stored at -80 degrees Celsius. However, this temperature requirement poses a challenge for storage and distribution in low-resource environments. The researchers discovered that when stored at +4 degrees Celsius or at room temperature for up to three months, 17 out of 18 peptides remained stable, with only one peptide showing an increase in an oxidized methionine residue. These findings suggest that peptide-based vaccines can be made more accessible to resource-limited communities. [Extracted from the article]

A new study conducted by researchers at Mayo Clinic Health System has found a potential link between the respiratory syncytial virus (RSV) vaccine and the onset of polymyalgia rheumatica (PMR), a chronic inflammatory disorder that causes stiffness and pain in the joints. Previous studies have linked PMR symptoms to influenza and COVID-19 vaccines, but this is the first report of a potential association with the RSV vaccine. The study highlights the importance of reviewing immunization history in patients with PMR symptoms to rule out any potential adverse effects. Further research is needed to fully understand the relationship between the RSV vaccine and PMR. [Extracted from the article]

A recent study evaluated the use of cell-free protein synthesis (CFPS) to produce a potential vaccine antigen for Chlamydia trachomatis, the most prevalent bacterial sexually transmitted pathogen worldwide. The study found that CFPS-produced CT584, a protein from the chlamydial type three secretion system, retained a native-like structure. However, immunization with CT584 alone did not provide protection against Chlamydia muridarum infection in mice. Despite this, the study highlights the potential of CFPS for producing other chlamydial antigens, offering a flexible and rapid technique for antigen production. Please note that this study has not yet undergone peer review. [Extracted from the article]

A recent study conducted at the State University of New York (SUNY) Buffalo has found that a specific fraction of the Chilean soapbark tree, Quillaja Saponaria (QS-18), can be a safe and effective adjuvant in cancer gene therapy. The researchers compared the adjuvanticity and toxicity of QS-18 and QS-21, and found that QS-18, when formulated in liposomes, did not induce local reactogenicity or significant weight loss in mice. Furthermore, QS-18 peptide particles induced higher levels of cancer-specific T cells compared to QS-21 particles, without increased toxicity. The study suggests that QS-18 could potentially reduce production costs for vaccine adjuvant systems. Further research is needed to assess the immunogenic, reactogenic, and toxicological profiles of liposomal QS-18 in other animal species. [Extracted from the article]

A patent application has been filed for a new immunogenic composition that delivers a peptide antigen to induce an immune response. The composition utilizes polymer nanoparticles that contain a peptide antigen linked to a peptide tag, along with an adjuvant. The nanoparticles can enter immune cells and generate an immune response to the peptide antigen. The method has the potential to be used in personalized cancer vaccines that target tumor-specific neoantigens. [Extracted from the article]

A report from the University of South China discusses the role and development of peptide vaccines in the treatment of cervical cancer. The research highlights the advantages of therapeutic cancer vaccine strategies in targeting and mediating immune responses. Peptide vaccines, which can be prepared through chemical synthesis techniques, have shown the ability to generate specific immune responses and modulate the tumor microenvironment without significant side effects. The article reviews the progress in targeting cervical cancer with peptide vaccines, including adjuvant selection and ideal target selection. [Extracted from the article]

A recent report from researchers at Mashhad University of Medical Sciences in Iran discusses the use of peptide vaccines in cancer immunotherapy. The study focuses on the effects of peptide-based vaccinations on cytokines in activating CD8+ T cells against tumor antigens. The researchers found that peptide-based vaccines increased the secretion of IFN-g, TNF-a, IL-2, and IL-12, which are cytokines that can suppress tumor cell growth. The study suggests that peptide-based vaccines have potential in enhancing immune responses against cancer. [Extracted from the article]

A study conducted by researchers at Fujian Medical University in China evaluated the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer. The researchers identified proteins undergoing translatome and exhibiting mutations in lung cancer cells and analyzed their immunogenicity. They synthesized ten neoantigen peptides and found that eight of them had strong immunogenicity. In vivo experiments in mice showed that the neoantigen peptide vaccine group exhibited a significant tumor growth inhibition effect. This research provides evidence for the potential of neoantigen peptide vaccines in cancer immunotherapy. [Extracted from the article]

Researchers from Mawlana Bhashani Science and Technology University have conducted a study on the potential of a peptide vaccine against Shigella flexneri, a significant cause of diarrhea in Bangladesh. The current treatment methods using antibiotics are ineffective, and antibiotic-resistant strains are emerging. The researchers chemically synthesized a peptide from the Ferric enterobactin protein and tested it in mice models. The results showed that the peptide was highly immunogenic and protected the vaccinated mice from infection. This study provides evidence for the potential of the peptide vaccine against Shigella flexneri and suggests further evaluation for its suitability in combating Shigellosis. [Extracted from the article]

A recent report discusses research on the design of neoantigen-based vaccines for cancer immunotherapy. The researchers developed a novel algorithm called UltraMutate, which combines Reinforcement Learning and Monte Carlo Tree Search to identify peptide mutations that have enhanced binding affinities to target human leukocyte antigen (HLA) molecules while maintaining homology with the original neoantigen. The algorithm outperformed existing methods in identifying affinity-enhancing mutations and showed potential in designing peptide vaccines for Human Papillomavirus and Human Cytomegalovirus. This research has implications for personalized immunotherapy. [Extracted from the article]

This document provides information about a clinical trial, NCT06414733, which is currently in the recruitment phase. The trial aims to study the side effects and optimal dosage of vaccine therapy for patients with metastatic solid tumors. The trial will use vaccines made from antibodies and peptides combined with tumor cells to stimulate the body's immune response against tumor cells. The trial plans to enroll 42 participants with metastatic or unresectable breast or gastrointestinal cancer, and it is expected to be completed by June 2027. The responsible party for the trial is Pravin T.P Kaumaya from Indiana University. [Extracted from the article]